Literature DB >> 7696451

Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis.

M Nyman-Pantelidis1, A Nilsson, Z G Wagner, O Borgå.   

Abstract

METHODS: The retrograde spread of two budesonide enema formulations with different viscosities was investigated. The study design was open, randomized and two-period crossover. Three female and two male patients (age range: 35-45 years) with distal ulcerative colitis or proctitis participated. Both enema formulations contained a dose of 2 mg budesonide/100 mL. An unabsorbable radioactive marker (99mTc-labelled human serum albumin microcolloid) was added to the enema just before administration. All doses were given in the evening with the patients lying in a supine position during the whole investigation. The intestinal spread was followed for 8 h using scintigraphic imaging. Plasma samples for budesonide assay were taken during the 12 h after administration of the low viscosity enema.
RESULTS: Budesonide plasma levels were measurable for up to 4-6 h. Cmax was 2.5 nmol/L (range: 0.9-4.5 nmol/L) and was attained in 1.5 h (range 1-3 h). The patients had no difficulty in retaining the enemas. There was a statistically significant difference in spread between the low and high viscosity enema. The low viscosity enema spread over an area situated between the rectum and the splenic flexure. The spread occurred mainly in the first 15 min after administration. In contrast, the high viscosity enema, in most cases, spread only over a minor part of this area and the rate and extent of spreading was also more variable with this formulation.
CONCLUSION: The spread of a low viscosity enema appears to be well suited for the treatment of proctitis and distal colitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7696451     DOI: 10.1111/j.1365-2036.1994.tb00339.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Rectal pharmacokinetics of budesonide.

Authors:  K Dahlstrom; S Edsbacker; A Kallen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Budesonide for the treatment of ulcerative colitis.

Authors:  Maisa I Abdalla; Hans Herfarth
Journal:  Expert Opin Pharmacother       Date:  2016-06-16       Impact factor: 3.889

3.  Locally and systemically active glucocorticosteroids modify intestinal absorption of lipids in rats.

Authors:  A Thiesen; G E Wild; M Keelan; M T Clandinin; L B Agellon; A B R Thomson
Journal:  Lipids       Date:  2002-02       Impact factor: 1.880

4.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

Review 5.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

6.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 7.  Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.

Authors:  C M Spencer; D McTavish
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

8.  Stimulating effect of glucocorticosteroids on intestinal fructose transport in rats is increased by feeding a saturated fatty acid diet.

Authors:  A Thiesen; M Keelan; G E Wild; M T Clandinin; A B R Thomson
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

9.  Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial.

Authors:  Emanuel E Canfora; Christina M van der Beek; Johan W E Jocken; Gijs H Goossens; Jens J Holst; Steven W M Olde Damink; Kaatje Lenaerts; Cornelis H C Dejong; Ellen E Blaak
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

10.  Development of a Mucoadhesive in Situ Gelling Formulation for the Delivery of Lactobacillus gasseri into Vaginal Cavity.

Authors:  Barbara Vigani; Angela Faccendini; Silvia Rossi; Giuseppina Sandri; Maria Cristina Bonferoni; Pietro Grisoli; Franca Ferrari
Journal:  Pharmaceutics       Date:  2019-10-03       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.